Menetrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach

被引:79
作者
Coffey, Robert J.
Washington, Mary Kay
Corless, Christopher L.
Heinrich, Michael C.
机构
[1] Vanderbilt Univ, Dept Med, Med Ctr, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Dept Cell & Dev Biol, Med Ctr, Nashville, TN USA
[3] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA
[4] Nashville Vet Affairs Med Ctr, Nashville, TN USA
[5] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA
[6] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA
[7] Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA
[8] Portland VA Med Ctr, Portland, OR USA
关键词
D O I
10.1172/JCI30491
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Menetrier disease and gastrointestinal stromal tumors (GISTs) are hyperproliferative disorders of the stomach caused by dysregulated receptor tyrosine kinases (RTKs). In Menetrier disease, overexpression of TGF-alpha, a ligand for the RTK EGFR, results in selective expansion of surface mucous cells in the body and fundus of the stomach. In GISTs, somatic mutations of the genes encoding the RTK KIT (or PDGFRA in a minority of cases) result in constitutive kinase activity and neoplastic transformation of gut pacemaker cells (interstitial cells of Cajal). On the basis of the involvement of these RTKs in the pathogenesis of these disorders, Menetrier disease patients have been effectively treated with a blocking monoclonal antibody specific for EGFR and GIST patients with KIT and PDGFRA tyrosine kinase inhibitors.
引用
收藏
页码:70 / 80
页数:11
相关论文
共 111 条
[1]   Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site [J].
Antonescu, CR ;
Viale, A ;
Sarran, L ;
Tschernyavsky, SJ ;
Gonen, M ;
Segal, NH ;
Maki, RG ;
Socci, ND ;
DeMatteo, RP ;
Besmer, P .
CLINICAL CANCER RESEARCH, 2004, 10 (10) :3282-3290
[2]   Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation [J].
Antonescu, CR ;
Besmer, P ;
Guo, TH ;
Arkun, K ;
Hom, G ;
Koryotowski, B ;
Leversha, MA ;
Jeffrey, PD ;
Desantis, D ;
Singer, S ;
Brennan, MF ;
Maki, RG ;
DeMatteo, RP .
CLINICAL CANCER RESEARCH, 2005, 11 (11) :4182-4190
[3]  
BARNARD JA, 1994, J BIOL CHEM, V269, P22817
[4]   Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor [J].
Bauer, Sebastian ;
Yu, Lynn K. ;
Demetri, George D. ;
Fletcher, Jonathan A. .
CANCER RESEARCH, 2006, 66 (18) :9153-9161
[5]   LOCALIZATION OF TRANSFORMING GROWTH FACTOR-ALPHA AND ITS RECEPTOR IN GASTRIC-MUCOSAL CELLS - IMPLICATIONS FOR A REGULATORY ROLE IN ACID-SECRETION AND MUCOSAL RENEWAL [J].
BEAUCHAMP, RD ;
BARNARD, JA ;
MCCUTCHEN, CM ;
CHERNER, JA ;
COFFEY, RJ .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (03) :1017-1023
[6]  
BENJAMIN RS, 2003, P AN M AM SOC CLIN, V22, P814
[7]   Oncogenic kinase signalling [J].
Blume-Jensen, P ;
Hunter, T .
NATURE, 2001, 411 (6835) :355-365
[8]   ACTIVATION OF THE HUMAN C-KIT PRODUCT BY LIGAND-INDUCED DIMERIZATION MEDIATES CIRCULAR ACTIN REORGANIZATION AND CHEMOTAXIS [J].
BLUMEJENSEN, P ;
CLAESSONWELSH, L ;
SIEGBAHN, A ;
ZSEBO, KM ;
WESTERMARK, B ;
HELDIN, CH .
EMBO JOURNAL, 1991, 10 (13) :4121-4128
[9]   IMMUNOLOCALIZATION OF TRANSFORMING GROWTH-FACTOR-ALPHA IN NORMAL AND DISEASED HUMAN GASTRIC-MUCOSA [J].
BLUTH, RF ;
CARPENTER, HA ;
PITTELKOW, MR ;
PAGE, DL ;
COFFEY, RJ .
HUMAN PATHOLOGY, 1995, 26 (12) :1333-1340
[10]   REGULATION OF TERMINAL DIFFERENTIATION OF ZYMOGENIC CELLS BY TRANSFORMING GROWTH-FACTOR-ALPHA IN TRANSGENIC MICE [J].
BOCKMAN, DE ;
SHARP, R ;
MERLINO, G .
GASTROENTEROLOGY, 1995, 108 (02) :447-454